AR126977A2 - Composiciones de forma de dosificación que comprenden un inhibidor de tirosina cinasa de bruton - Google Patents
Composiciones de forma de dosificación que comprenden un inhibidor de tirosina cinasa de brutonInfo
- Publication number
- AR126977A2 AR126977A2 ARP220102392A ARP220102392A AR126977A2 AR 126977 A2 AR126977 A2 AR 126977A2 AR P220102392 A ARP220102392 A AR P220102392A AR P220102392 A ARP220102392 A AR P220102392A AR 126977 A2 AR126977 A2 AR 126977A2
- Authority
- AR
- Argentina
- Prior art keywords
- bruton
- free base
- crystalline salts
- kinase inhibitor
- kinase
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 229940125814 BTK kinase inhibitor Drugs 0.000 title 1
- 239000002552 dosage form Substances 0.000 title 1
- 239000012458 free base Substances 0.000 abstract 4
- 150000003839 salts Chemical class 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 abstract 2
- 229920001577 copolymer Polymers 0.000 abstract 2
- 229940043355 kinase inhibitor Drugs 0.000 abstract 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 abstract 2
- 239000007962 solid dispersion Substances 0.000 abstract 2
- 102000001714 Agammaglobulinaemia Tyrosine Kinase Human genes 0.000 abstract 1
- 108010029445 Agammaglobulinaemia Tyrosine Kinase Proteins 0.000 abstract 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 abstract 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 abstract 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 abstract 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 239000002202 Polyethylene glycol Substances 0.000 abstract 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000001530 fumaric acid Substances 0.000 abstract 1
- 229920000578 graft copolymer Polymers 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
- 229920001223 polyethylene glycol Polymers 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 229920002689 polyvinyl acetate Polymers 0.000 abstract 1
- 239000011118 polyvinyl acetate Substances 0.000 abstract 1
- 239000007916 tablet composition Substances 0.000 abstract 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 abstract 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La invención se refiere, en general, a composiciones farmacéuticas en comprimido que comprenden ácido fumárico y el compuesto de base libre de (S)-2-(3-(hidroximetil)-1-metil-5-((5-(2-metil-4-(oxetan-3-il)piperazin-1-il)piridin-2-il)amino)-6-oxo-1,6-dihidro-[3,4-bipiridin]-2-il)-7,7-dimetil-2,3,4,6,7,8-hexahidro-1H-ciclopenta[4,5]pirrolo[1,2-a]pirazin-1-ona que es un inhibidor de la tirosina cinasa de Bruton. La invención se refiere además a dispersiones sólidas amorfas que comprenden al menos un polímero y la base libre del compuesto inhibidor de la cinasa de Bruton. La invención se refiere además a sales cristalinas de mesilato, sales cristalinas de cloruro y sales cristalinas de sulfato de la base libre del compuesto inhibidor de la cinasa de Bruton. En algunos aspectos, las sales cristalinas son polimorfos individuales. Reivindicación 1: Una composición de dispersión sólida amorfa adecuada para el tratamiento de trastornos mediados por la actividad de la tirosina cinasa de Bruton, caracterizada porque comprende: (1) un componente polimérico, en donde el componente polimérico es copolímero de metacrilato, copolímero de amino metacrilato, polietilenglicol, acetato de polivinilo, o copolímero injertado de polivinilcaprolactama, o cualquier combinación de los mismos; y (2) de 20% en peso a 50% en peso de una base libre de estructura [1].
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ARP220102392A AR126977A2 (es) | 2022-09-05 | 2022-09-05 | Composiciones de forma de dosificación que comprenden un inhibidor de tirosina cinasa de bruton |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ARP220102392A AR126977A2 (es) | 2022-09-05 | 2022-09-05 | Composiciones de forma de dosificación que comprenden un inhibidor de tirosina cinasa de bruton |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR126977A2 true AR126977A2 (es) | 2023-12-06 |
Family
ID=89309898
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220102392A AR126977A2 (es) | 2022-09-05 | 2022-09-05 | Composiciones de forma de dosificación que comprenden un inhibidor de tirosina cinasa de bruton |
Country Status (1)
| Country | Link |
|---|---|
| AR (1) | AR126977A2 (es) |
-
2022
- 2022-09-05 AR ARP220102392A patent/AR126977A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018008754A (es) | Composiciones de forma de dosificacion que comprenden un inhibidor de tirosina cinasa de bruton. | |
| US12454521B2 (en) | Targeted protein degradation | |
| JP6045519B2 (ja) | タンパク質キナーゼ阻害剤としての化合物および組成物 | |
| PH12022552745A1 (en) | [1,3]DIAZINO[5,4-d]PYRIMIDINES AS HER2 INHIBITORS | |
| ES2635003T3 (es) | Dihidroquinoxalinonas y dihidropiridopirazinonas modificadas inhibidoras de proteína BET | |
| US20190292205A1 (en) | Novel 2,3-Dihydro-1h-imidazo{1,2-a}pyrimidin-5-one and this 1,2,3,4-tetrahydropyrimido{1,2-a}pyrimidin-6-one Derivatives Comprising a Substituted Morpholine, Preparation Thereof and Pharmaceutical Use Thereof | |
| JP2023538520A (ja) | Ｉｋａｒｏｓ又はａｉｏｌｏｓによって媒介される障害に対する有利な治療法 | |
| AU2017286654A1 (en) | Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases | |
| NZ731337A (en) | Compounds useful as inhibitors of atr kinase | |
| WO2017007658A1 (en) | A combination for immune mediated cancer treatment | |
| JP2015516392A5 (es) | ||
| AU2011246574A1 (en) | New combination therapy in treatment of oncological and fibrotic diseases | |
| JP2015500862A5 (es) | ||
| RU2012120901A (ru) | Способ лечения пролиферативных расстройств и других патологических состояний, опосредованных действием киназ bcr-abl, c-kit, ddr1, ddr2 или pdgf-r | |
| NO331174B1 (no) | Substituerte 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazinderivater og deres anvendelse som neurokininantagonister | |
| CA2952526A1 (en) | Bet-protein inhibiting 3,4-dihydropyrido[2,3-b]pyrazinones with meta-substituted aromatic amino- or ether groups | |
| JP2016520637A5 (es) | ||
| JP7293108B2 (ja) | Ａｘｌ阻害剤とＥＧＦＲチロシンキナーゼ阻害薬との併用治療法 | |
| RU2011105059A (ru) | Применение производных пиримидиламинобензамида для лечения фиброза | |
| CA2611481A1 (en) | Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators | |
| MX2023009954A (es) | Compuestos de aminopirimidina y métodos de uso de estos. | |
| AR126977A2 (es) | Composiciones de forma de dosificación que comprenden un inhibidor de tirosina cinasa de bruton | |
| US20250326753A1 (en) | Dual cxcr4-btk inhibitors | |
| AU2009319050B2 (en) | Pharmaceutical combinations comprising a pyrido [4, 3-d] pyrimidine derived Hsp90-inhibitor and a HER2 inhibitor | |
| CN111727183A (zh) | 5-氟-4-(4-氟-2-甲氧基苯基)-n-{4-[(s-甲基磺亚胺酰基)甲基]吡啶-2-基}吡啶-2-胺用于治疗弥漫性大b细胞淋巴瘤中的用途 |